Clinical Trials
2 trialsNCT01142401 2023-11-27
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00574236 2019-12-13
Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer
University of Wisconsin, Madison
Phase 2 Terminated